Global Ophthalmic Market Analysis & Forecasts to 2012 : Market Research Report

Global Ophthalmic Market Analysis & Forecasts to 2012

Published by: Visiongain

Published: Apr. 30, 2007 - 180 Pages

Chapter 1: Executive Summary: 1.1 The World Ophthalmics Market 2007; 1.2 Introduction to Ophthalmics, 2007; 1.3 Summary of Ophthalmics, 2007
Chapter 2: The World Ophthalmic Pharmaceutical Market: 2.1 Ophthalmic Industry Segmentation; 2.2 The Worldwide Ophthalmic Pharmaceutical Market, 2007-2012; 2.3 An Overview of the Eye; 2.4 The Leading Ophthalmic Disease Profiles:Description and Prevalence; 2.5 The Top 10 Major Selling Ophthalmic Drugs and Their Manufacturers, 2005; 2.6 Key Companies in the Ophthalmic Pharmaceutical Market; 2.7 Drivers for the Ophthalmic Market; 2.8 Restraints for the Ophthalmic Market; 2.9 Strategic Options in the Ophthalmic Industry 2.10 The Economic Cost of Eye Diseases
Chapter 3. The Worldwide Glaucoma Pharmaceuticals Market: 3.1 An Introduction to Glaucoma: the Leading Cause of Blindness in the Ophthalmic Market; 3.2 Primary Open Angle Glaucoma: The Most Common Form; 3.3 Closed Angle Glaucoma - Less Common; 3.4 Secondary Glaucoma: Mild or Severe?; 3.5 Normal Tension Glaucoma (NTG) - Optic Nerve Damage; 3.6 Pigmentary Glaucoma Causes Increase in Eye Pressure; 3.7 Current Glaucoma Drug Treatments Available; 3.8 Beta Blockers: The Primary Treatment for Glaucoma or Not?; 3.9 Prostaglandin Analogues the Leading Glaucoma Treatment; 3.10 Docosanoids as Novel Glaucoma Therapies; 3.11 Miotics - Many Drugs Available; 3.12 Carbonic Anhydrase Inhibitors - Limited Choice of Drugs; 3.13 Alpha Agonists - Limited Availability; 3.14 Hyperosmolars - Uncommon Glaucoma Treatment; 3.15 Combination Therapies - Future Looks Promising; 3.16 Glaucoma Drugs Preferred Than Surgery; 3.17 Glaucoma Worldwide Market: A Dormant Giant; 3.18 Prostaglandins Treatment Lead the Glaucoma Market; 3.19 Key Drivers in the Glaucoma Market 3.20 Some Restraints in the Glaucoma Market; 3.21 The Top 10 Selling Glaucoma Drugs in 2005; 3.22 Pfizer's Blockbuster dominates the Glaucoma Market; 3.23 The World Market Share of Top 10 Selling Glaucoma Drugs, 2005; 3.24 The Market Share of the Top 10 Selling Glaucoma Drugs by Company; 3.25 Company Market Share (%) of the World Top 10 Selling Glaucoma Drugs, 2005; 3.26 Glaucoma Pipeline Products, 2007; 3.27 Glaucoma Market Opportunities: Door Wide Open
Chapter 4: Age Related Macular Degeneration (AMD) Pharmaceuticals Market: 4.1 An Introduction to Wet and Dry AMD: The Cause of Vision Loss in the Senior Population; 4.2 Risk Factors Associated with AMD; 4.3 AMD Prevalence; 4.4 Dry AMD: No Proven Treatments, Yet; 4.5 Drug Treatments for Wet AMD; 4.6 Current AMD Drug Therapies; 4.7 Lucentis v Avastin - cost and dose but no clinical trial; 4.8 Future Treatments for AMD; 4.9 Drug Therapies in the AMD Market Provides Commercial Targets; 4.10 Market Drivers in the AMD Market; 4.11 Market Restraints in the AMD Market; 4.12 Lucentis Revenues: An eye opener; 4.13 The Worldwide AMD Drug Market; 4.14 Pipeline Products in the AMD Market; 4.15 AMD Market Opportunities: Many Targets to Hit
Chapter 5: Ocular Allergies Pharmaceuticals Market: 5.1 An Introduction to Ocular Allergies; 5.2 Seasonal & Perennial Allergic Conjunctivitis - Most Common Types; 5.3 Giant Papillary Conjunctivitis - Inflammatory Disorder; 5.4 Vernal Keratoconjunctivitis - the Recurring Disease; 5.5 Atopic Keratoconjunctivitis - Year Round Disease; 5.6 An Overview of Ocular Allergy Drug Treatments; 5.7 Antihistamines (H1-Receptor Antagonists); 5.8 Mast Cell Stabilisers Have Slow Onset of Action; 5.9 Topical NSAIDs Have High Adverse Effect Incidence; 5.10 Corticosteroids - Long-term Use Dangerous; 5.11 Long Lasting Dual/Multiple-Action Agents; 5.12 The Deciding Factor Between Systemic and Topical Medications; 5.13 Alcon's Patanol: Dominates the Ocular Allergy Market; 5.14 Market Drivers in the Ocular Allergy Market; 5.15 Market Restraints in the Ocular Allergy Market; 5.16 The Ocular Allergy Worldwide Market: Alcon's Patanol Dominates; 5.17 Ocular Allergy Pipeline Products, 2007; 5.18 Ocular Allergy Market Opportunities; 5.19 The Future for Ocular Allergies
Chapter 6: Dry Eye Syndrome Pharmaceuticals Market: 6.1 Introduction to Dry Eye Syndrome - Tear Film Disorder; 6.2 The Causes of Dry Eye Syndrome is Associated With Aging; 6.3 High-Risk Populations for Dry Eye Syndrome; 6.4 An Overview of DES Drug Treatments; 6.5 Drug Treatment of Dry Eye - Artificial Tears Remain 1st Choice; 6.6 Low Viscosity Artificial Tears; 6.7 Moderate Viscosity Artificial Tears; 6.8 High Viscosity Artificial Tears; 6.9 Gel Formulations - The Novel System; 6.10 Lubricating Ointments - Uncommonly Used; 6.11 Restasis: Only Prescription Eye Drop; 6.12 Mechanism of Action of Restasis; 6.13 Allergy or Dryness: The Argument Continues; 6.14 DES Market Drivers; 6.15 DES Market Restraints; 6.16 The Dry Eye Worldwide Drug Market: Restasis Leads the Market; 6.17 Pipeline Products in the Dry Eye Market; 6.18 Secretagogues: New Treatment Perhaps?; 6.19 DES Market Opportunities
Chapter 7: Ocular Infections Pharmaceuticals Market: 7.1 An Introduction to Ocular Infections; 7.2 Hordeolum - Most Common Eyelid Lesions in the US; 7.3 Blepharitis - Inflammation of the Eyelids; 7.4 Introduction to Conjunctivitis - Pink Eye; 7.5 Bacterial Conjunctivitis - The Self-Limited illness; 7.6 Viral Conjunctivitis - Affects All Ages; 7.7 Epidemic Keratoconjunctivitis - Highly Contagious; 7.8 Pharyngoconjunctival Fever - Child Fever; 7.9 Keratitis - The Corneal Infection; 7.10 Herpes Simplex Keratitis - Common Human Infection; 7.11 Bacterial Keratitis - Sight-Threatening Disease; 7.12 Fungal Keratitis - Remains a Challenge; 7.13 Acanthamoeba Keratitis - Parasite Invader; 7.14 Ocular Infection Drug Treatments; 7.15. Topical Antibiotics: Fluroquinolones; 7.16 Systemic Antibacterials; 7.17 Antivirals - Choice Limited; 7.18 Antifungals - Wide Range Available; 7.19 Ocular Infection Market Drivers; 7.20 Ocular Infection Market Restraints; 7.21 The Worldwide Ocular Infection Drug Market:Vigamox Dominates; 7.22 Ocular Infection Pipeline Products, 2007; 7.23 Ocular Infection Market Opportunities
Chapter 8: Ocular Inflammatory Pharmaceuticals Market: 8.1 Ocular Inflammatory Disorders: An Overview; 8.2 Chalazion - Painless But Deadly; 8.3 Uvetitis - Common Cause of Vision Loss in the Young; 8.4 Topical Corticosteroids Remains the Primary Ocular Anti-Inflammatory Therapy; 8.5 Topical Corticosteroids Available on the 2007 Market; 8.6 Corticosteroid Ointment Treatments; 8.7 Oral Corticosteroids - Not Commonly Used; 8.8 Topical NSAIDS - Stings on Treatment; 8.9 COX-2 Inhibitors - Only One Remains; 8.10 Ocular Inflammation Market Drivers; 8.11 Ocular Inflammation Market Restraints; 8.12 The Worldwide Ocular Inflammation Drug Market, 2007-2012; 8.13 Ocular Inflammatory Pipeline Products, 2007; 8.14 Ocular Inflammatory Market Opportunities
Chapter 9: Conclusion: 9.1 The Ophthalmic Pharmaceutical Market is Headed for High Consistent; Financial Growth
List of Tables: Table 1.1 Total Worldwide Pharmaceutical Ophthalmic Market Forecast ($bn), 2007-2012; Table 1.2 Top Three Selling Ophthalmic Drugs in 2006; Table 1.3 Xalatan Revenue Forecast ($m), 2007-2012; Table 1.4 Cosopt Revenue Forecast ($m), 2007-2012; Table 1.5 Lucentis Revenue Forecast ($m), 2007-2012; Table 2.1 Total Worldwide Pharmaceutical Ophthalmic Market Forecast ($bn), 2007-2012; Table 2.2 Worldwide Pharmaceutical Ophthalmic Market Forecast by Disease ($bn), 2007-2012; Table 2.3 Ophthalmic Disease Area Market Share (%), 2006, 2009 and 2012; Table 2.4 Prevalence of Cataract, AMD and Open Angle Glaucoma Among Adults 40 Years and Older in the US, 2004; Table 2.5 Prevalence of Diabetic Retinopathy Among Adults in the US, 2004; Table 2.6 Estimated Prevalence of Myopia and Hyperopia Among Adults in the US, 2006; Table 2.7 Revenues ($m) of the Top 10 Selling Ophthalmic Drugs, 2005; Table 2.8 Top 10 Selling Ophthalmic Drugs by Market Share (%), 2005; Table 2.9 Advantages and Disadvantages of Ophthalmic Drug Delivery Routes; Table 3.1 Current Beta Blockers used to treat Glaucoma, 2007; Table 3.2 Current Prostaglandins used to treat Glaucoma, 2007; Table 3.3 Current Miotics used to treat Glaucoma, 2007; Table 3.4 Current Carbonic Anhydrase Inhibitors used to treat Glaucoma, 2007; Table 3.5 Current Combination therapies used to treat Glaucoma, 2007; Table 3.6 Summary of Glaucoma drugs by Company, 2007; Table 3.7 Total World Glaucoma Drug by Treatment Class Market Forecast ($bn), 2007-2012; Table 3.8 Total World Glaucoma Drug by Treatment Class Market Share Forecast (%), 2007-2012; Table 3.9 Top 10 Selling ($m) Glaucoma Drugs by Company, 2005; Table 3.10 Market Share (%) of Top 10 Selling Glaucoma drugs, 2005; Table 3.11 Market Share (%) of Top 10 Selling Glaucoma Drugs by Company, 2005; Table 3.12 Glaucoma Pipeline Products, 2007; Table 4.1 The prevalence of wet AMD worldwide in 2006 and 2025; Table 4.2 The prevalence of dry AMD worldwide in 2006 and 2025; Table 4.3 Current Drug Treatments for Wet AMD, 2007; Table 4.4 Lucentis Revenue Forecast ($bn), 2007-2012; Table 4.5 Total Worldwide AMD Drug Market Forecast ($bn) 2007-2012; Table 4.6 Pipeline AMD Products, 2007; Table 5.1 Antihistamine Products; Table 5.2 Mast Cell Stabiliser Products; Table 5.3 Topical Corticosteroid Top Products; Table 5.4 Dual Action Products; Table 5.5 Summary of Products Used to Treat Ocular Allergies, 2007; Table 5.6 Total Worldwide Ocular Allergy Drug Market Forecast ($bn), 2007-2012; Table 5.7 Ocular Allergy Pipeline Products, 2007; Table 6.1 Low Viscosity Artificial Tear Products Available, 2007; Table 6.2 Moderate Viscosity Artificial Tear Products Available, 2007; Table 6.3 High Viscosity Artificial Tear Products Available, 2007; Table 6.4 Gel Formation Products Available, 2007; Table 6.5 Lubricating Ointment Products Available, 2007; Table 6.6 Summary of Available Drug Therapies Used to Treat Dry Eye Syndrome, 2007; Table 6.7 Total World Dry Eye Drug Market Revenue Forecast ($bn), 2007-2012; Table 7.1 List of Ocular Infections; Table 7.2 Systemic Antiviral Drug Products Available; Table 7.3 Antifungal Ophthalmic Drug Products; Table 7.4 Summary of Drug Products Available to Treat Ocular Infections; Table 7.5 Total World Ocular Infection Drug Market Revenue Forecast ($bn), 2007-2012; Table 7.6 Ocular Infection Product Pipeline, 2007; Table 8.1 Topical Corticosteroid Drugs Available; Table 8.2 Summary of Ocular Inflammatory Products; Table 8.3 Total World Ocular Inflammation Drug Market Revenue Forecast ($bn), 2007-2012; Table 8.4 Ocular Inflammation Pipeline Products, 2007
List of Graphs: Graph 1.1 Total World Ophthalmic Pharmaceutical Market Forecast ($bn), 2007-2012; Graph 2.1 Total World Ophthalmic Pharmaceutical Market Forecast ($bn), 2007-2012; Graph 2.2 Total World Ophthalmic Pharmaceutical Annual Growth Rate (%), 2007-2012; Graph 3.1 Glaucoma World Market Forecast ($bn), 2007-2012; Graph 3.2 Glaucoma World Market Growth (%), 2007-2012; Graph 4.1 The Prevalence of Three Major Causes of Blindness Among Adults 40 Years and Older in the US; Graph 4.2 Lucentis Revenue Forecast ($bn), 2007-2012; Graph 4.3 Lucentis Growth Forecast (%), 2007-2012; Graph 4.4 Total World AMD Market Revenue Forecast ($bn), 2007-2012; Graph 4.5 Total World AMD Market Growth Forecast (%), 2007-2012; Graph 5.1 Total World Ocular Allergy Market Revenue Forecast ($bn), 2007-2012; Graph 5.2 Total World Ocular Allergy Market Growth Forecast (%), 2007-2012; Graph 6.1 Total World Dry Eye Market Revenue Forecast ($bn), 2007-2012; Graph 6.2 Total World Dry Eye Market Growth Forecast (%), 2007-2012; Graph 7.1 Total World Ocular Infection Market Revenue Forecast ($bn), 2007-2012; Graph 7.2 Total World Ocular Infection Market Growth Forecast (%), 2007-2012; Graph 8.1 Total World Ocular Inflammation Market Revenue Forecast ($bn), 2007-2012; Graph 8.2 Total World Ocular Inflammation Market Growth Forecast (%), 2007-2012
List of Charts: Chart 2.1 Ophthalmic Disease Area Market Share (%), 2006; Chart 2.2 Ophthalmic Disease Area Market Share (%),2009; Chart 2.3 Ophthalmic Disease Area Market Share (%), 2012; Chart 2.4 Top 10 Selling Ophthalmic Drug Companies Market Share (%), 2005; Chart 3.1 Glaucoma Drug by Class Market Share (%), 2006; Chart 3.2 Glaucoma Drug by Class Market Share (%), 2009; Chart 3.3 Glaucoma Drug by Class Market Share (%), 2012; Chart 3.4 Market Share (%) of Top 10 Selling Glaucoma Drugs, 2005; Chart 3.5 Company Market Share (%) of Top 10 Selling Glaucoma Drugs, 2005; Chart 6.1 Causes of Dry Eye
List of Pictures: Picture 2.1 Anatomy of the Human Eye

Abstract

Driven by demographic trends, such as an increasing aged population, the global ophthalmic pharmaceutical market is set to become a serious growth area experiencing a compound annual growth rate of 11.11 per cent to 2012. This report explains just how this market will experience growth over the medium term future. Also do you know what the drivers and restraints of the market are? This report not only reveals these, but also details what strategies can be used to maximize profits from the drivers and restraints.

The Ophthalmic pharmaceutical market is divided into six major diseases.

These are:

Glaucoma
Age-related macular degeneration
Dry eye syndrome
Ocular allergy
Ocular inflammation
Ocular infection

In this report each one of these disease areas is examined in terms of market growth and revenue, current and future drug treatments, market analysis, and major companies involved.

According to the findings of this new 175+ page report, visiongain reveals that Glaucoma therapies are set to dominate the market over the forecast period (2007-2012), accounting for over 40 per cent of market revenues by 2012. Pfizer's product Xalatan, used to lower intraocular pressure to treat glaucoma, will generate blockbuster revenues in 2007, and continue to dominate the entire ophthalmic pharmaceutical market. However are there any others which can compete with this for market share or beat its dominance?

This report answers that question, with an analysis of other players in the market.

- Do you know what the market values of these major therapeutic areas of the ophthalmic world market are?

The report provides in-depth market analysis upon these areas, and extensively identifies both prescription and OTC ophthalmic drugs by disease and product type. The study also assess' the challenges faced by ophthalmic companies, and what exciting market opportunities exist in this up- and-coming therapeutic area.

Why You Must Buy This Report:

This report features over 50 tables, 20 graphs and charts, news, insights, the latest developments and an in depth survey of the opthalmic market with up-to-date analysis. This report is a vital addition to gaining an understanding of this highly profitable market sector and will give your company 'the edge' on your competitors. You can not afford to be without this latest report from visiongain.

With an increasing aged population and unmet medical needs this market is set to grow rapidly, but by how much? This report will tell you. Brought together in one easy to read, easily digested format, this report will keep you fully informed and up-to-date on the global ophthalmic pharmaceutical market.

Key questions that this report answers:

Which current or future therapies will drive the ophthalmic market?
The key companies involved in the market and their analysis?
What R&D opportunities exist for 'new comers'?
What are the current and future blockbusters within the ophthalmic industry?

Unique benefits to you when you order this report:

Immediate access through our exclusive Reading Room
You can access your report whichever country you are in without using harddrive space
Primary research throughout. You will not find this information anywhere else
Report stored in your reading room for ever
Full searchable report when you buy the company or corporate editions
Copies can be printed off for offline reading
Packed with charts, analysis, figures, graphs and tables

Please Note: Reports are sold based on the user licenses indicated. The Publisher delivers the report in Flash format via the publisher website, allowing viewing and printing capabilities only. Within one to two business days after placing the order, the Publisher will email the client with information on accessing their purchase. Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Global Ophthalmic Market Analysis & Forecasts to 2012

Table of Contents

Abstract